324 related articles for article (PubMed ID: 19088172)
1. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
[TBL] [Abstract][Full Text] [Related]
2. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.
Sun L; Zhang Q; Luan H; Zhan Z; Wang C; Sun B
J Exp Clin Cancer Res; 2011 Mar; 30(1):30. PubMed ID: 21414214
[TBL] [Abstract][Full Text] [Related]
3. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
6. [Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer].
Fang Q; Zhang L; Wang S; Ou W
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):518-22. PubMed ID: 21645456
[TBL] [Abstract][Full Text] [Related]
7. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
8. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
10. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
[TBL] [Abstract][Full Text] [Related]
11. Comparison of epidermal growth factor receptor mutations between primary tumors and lymph nodes in non-small cell lung cancer: a review and meta-analysis of published data.
Wang F; Fang P; Hou DY; Leng ZJ; Cao LJ
Asian Pac J Cancer Prev; 2014; 15(11):4493-7. PubMed ID: 24969875
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
Zhang C; Wei B; Li P; Yang K; Wang Z; Ma J; Guo Y
PLoS One; 2017; 12(3):e0173524. PubMed ID: 28333951
[TBL] [Abstract][Full Text] [Related]
13. EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.
Lavdovskaia ED; Iyevleva AG; Sokolenko AP; Mitiushkina NV; Preobrazhenskaya EV; Tiurin VI; Ivantsov AO; Bizin IV; Stelmakh LV; Moiseyenko FV; Karaseva NA; Orlov SV; Moiseyenko VM; Korzhenevskaya MA; Zaitsev IA; Kozak AR; Chistyakov IV; Akopov AL; Volkov NM; Togo AV; Imyanitov EN
Oncol Res Treat; 2018; 41(10):634-642. PubMed ID: 30145586
[TBL] [Abstract][Full Text] [Related]
14. Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis.
Wei Y; Shen K; Lv T; Wang X; Li C; Fan H; Lv Y; Liu H; Song Y
Lung Cancer; 2018 Nov; 125():43-50. PubMed ID: 30429037
[TBL] [Abstract][Full Text] [Related]
15. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
16. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.
Shimizu K; Yukawa T; Hirami Y; Okita R; Saisho S; Maeda A; Yasuda K; Nakata M
Target Oncol; 2013 Dec; 8(4):237-42. PubMed ID: 23212424
[TBL] [Abstract][Full Text] [Related]
18. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
20. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
